Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBITDA (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported EBITDA over the past 16 years, most recently at $5.3 million for Q2 2025.

  • For Q2 2025, EBITDA rose 147.88% year-over-year to $5.3 million; the TTM value through May 2025 reached -$17.2 million, down 181.17%, while the annual FY2025 figure was -$17.2 million, 94.99% down from the prior year.
  • EBITDA for Q2 2025 was $5.3 million at Lifecore Biomedical, Inc. \De\, up from -$9.0 million in the prior quarter.
  • Over five years, EBITDA peaked at $15.6 million in Q1 2024 and troughed at -$38.3 million in Q4 2021.
  • A 5-year average of -$7.2 million and a median of -$7.8 million in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: skyrocketed 301.78% in 2021 and later tumbled 377.37% in 2022.
  • Year by year, EBITDA stood at -$38.3 million in 2021, then surged by 67.28% to -$12.5 million in 2022, then surged by 213.56% to $14.2 million in 2023, then crashed by 113.78% to -$2.0 million in 2024, then skyrocketed by 371.92% to $5.3 million in 2025.
  • Business Quant data shows EBITDA for LFCR at $5.3 million in Q2 2025, -$9.0 million in Q1 2025, and -$2.0 million in Q4 2024.